New podcast episode:

Appetite, access and aftermath: The GLP-1 episode

GLP-1 medications are reshaping more than weight. They are altering behaviour, patient expectations and, increasingly, system pressures.

While public conversation often centres on transformation stories, the more meaningful shift is happening beneath the surface. Appetite regulation changes daily decision-making. Patients describe quieter food noise, altered reward patterns and different relationships with control. Those behavioural shifts matter clinically, but they also carry implications for service demand, long-term adherence and patient support.

For healthcare leaders, this is not simply a prescribing trend. It is a structural change in how patients engage with weight management, prevention and self-management.

At the same time, access remains complex. NHS capacity is stretched. Private provision is expanding. Regulatory oversight is evolving in real time. Alongside legitimate prescribing pathways, secondary and unregulated markets are emerging, raising safeguarding, continuity of care and data concerns.

There is also a secondary wave forming. New markets are developing around side effects, aesthetic changes and nutritional optimisation. This signals not just demand, but a broader reframing of weight management as an ongoing, multi-disciplinary journey.

GLP-1 sits at the intersection of clinical care, commercial influence and cultural momentum. For healthcare organisations, understanding the behavioural layer behind its uptake is essential. Not just to respond to demand, but to anticipate how this shift may influence patient expectations, service design and policy conversations in the years ahead.

In our latest podcast episode, we explore these tensions, from NHS impact to ethical positioning, and ask what responsible leadership looks like in the GLP-1 era.